Zobrazeno 1 - 10 of 84 pro vyhledávání: '"BR Avalos"'
2
Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2
Autor: EA Copelan, JC Biggs, JM Thompson, P Crilley, J Szer, JP Klein, N Kapoor, BR Avalos, I Cunningham, K Atkinson
Publikováno v: Blood. 78:838-843
One hundred twenty-seven patients with acute myelocytic leukemia (AML) were given busulfan 4 mg/kg on each of 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from an HLA-identical or o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::393f9e76ec7d3786ebcb8264ae2cffd0
https://doi.org/10.1182/blood.v78.3.838.bloodjournal783838
Zobrazit plný text záznamu
3
Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression
Autor: BR Avalos, VC Broudy, SK Ceselski, BJ Druker, JD Griffin, WP Hammond
Publikováno v: Blood. 84(3)
A decrease in responsiveness to granulocyte colony-stimulating factor (G-CSF) has been implicated in the pathophysiology of cyclic hematopoiesis. Using the canine model of cyclic neutropenia, we examined the response of neutrophil precursors to G-CSF
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052d6ade993fef79002c53ffdd7dffde
https://pubmed.ncbi.nlm.nih.gov/7519075
Zobrazit plný text záznamu
4
Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY
Autor: Br, Avalos, Jl, Klein, Kapoor N, Pj, Tutschka, Jp, Klein, Ea, Copelan
Publikováno v: Europe PubMed Central
The results of autologous and allogeneic BMT in 44 patients with Hodgkin's or non-Hodgkin's lymphomas who received preparative therapy consisting of busulfan 16 mg/kg and cyclophosphamide 120 mg/kg are presented. Sixteen patients are surviving free o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8b1064f68827fbf2cb43afb3ffa2b5d7
https://pubmed.ncbi.nlm.nih.gov/8401359
Zobrazit plný text záznamu
5
Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines
Autor: BR Avalos, JC Gasson, C Hedvat, SG Quan, GC Baldwin, RH Weisbart, RE Williams, DW Golde, JF DiPersio
Publikováno v: Blood. 75(4)
Human granulocyte colony-stimulating factor (G-CSF) is a regulatory glycoprotein that stimulates the production of neutrophilic granulocytes from committed hematopoietic progenitor cells both in vitro and in vivo. In this report, we show that biosynt
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbb9af05b11528a1ab7841eeb52acd6b
https://pubmed.ncbi.nlm.nih.gov/1689190
Zobrazit plný text záznamu
6
K562 cells produce and respond to human erythroid-potentiating activity
Autor: BR Avalos, SE Kaufman, M Tomonaga, RE Williams, DW Golde, JC Gasson
Publikováno v: Blood. 71(6)
Human erythroid-potentiating activity (EPA) is a 28,000 mol wt glycoprotein that stimulates the growth of erythroid progenitors in vitro and enhances colony formation by the K562 human erythroleukemia cell line. EPA has potent protease inhibitory act
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94dfe5d2f74f0ed961d8c3c9dd38e140
https://pubmed.ncbi.nlm.nih.gov/2836003
Zobrazit plný text záznamu
7
Akademický článek
Hereditary chronic neutrophilic leukemia in a four-generation family without transformation to acute leukemia.
Autor: Lance A; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Chiad Z; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Seegers SL; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Paschall SC; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Drummond K; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Steuerwald NM; Molecular Biology Core Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Yang HT; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Chen J; Department of Biostatistics and Data Sciences, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Voorhees PM; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Avalos BR; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA., Druhan LJ; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Publikováno v: American journal of hematology [Am J Hematol] 2024 Oct; Vol. 99 (10), pp. 1877-1886. Date of Electronic Publication: 2024 Jun 27.
Zobrazit plný text záznamu
8
Akademický článek
Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy.
Autor: Foureau DM; Immune Monitoring Core Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC. Electronic address: david.foureau@atriumhealth.org., Guo F; Immune Monitoring Core Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC., Steuerwald NM; Molecular Biology Core Facility, Levine Cancer Institute, Charlotte, NC., Druhan LJ; Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC., Avalos BR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Copelan E; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Sun D; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Hu B; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Moyo T; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Jacobs R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Park S; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC., Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Publikováno v: Experimental hematology [Exp Hematol] 2024 Jan; Vol. 129, pp. 104125. Date of Electronic Publication: 2023 Oct 30.
Zobrazit plný text záznamu
9
Editorial & Opinion
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Autor: Chojecki AL; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. Electronic address: Aleksander.Chojecki@atriumhealth.org., Arnall J; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Boselli D; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Patel R; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Chiad Z; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., DiSogra KY; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Karabinos A; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Chen T; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Cruz A; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Verbyla A; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Ai J; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Knight TG; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Ragon BK; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Shah NA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Sanikommu SR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Symanowski J; Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Avalos BR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Copelan EA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Publikováno v: Leukemia research [Leuk Res] 2022 Aug; Vol. 119, pp. 106904. Date of Electronic Publication: 2022 Jun 21.
Zobrazit plný text záznamu
10
Editorial & Opinion
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF).
Autor: Chojecki AL; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., DiSogra KY; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Arnall J; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Cowgill N; Atrium Health Specialty Pharmacy Service, Atrium Health, Charlotte, NC, USA., Soni A; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Packman CH; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Sanikommu SR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Shah NA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Ragon BK; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Knight TG; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Ai J; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Avalos BR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Copelan EA; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2022 Jun; Vol. 63 (6), pp. 1515-1517. Date of Electronic Publication: 2022 Feb 02.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje